SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-21-013580
Filing Date
2021-03-25
Accepted
2021-03-25 21:28:59
Documents
1
Period of Report
2021-03-25

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3182
  Complete submission text file 0000899243-21-013580.txt   4897
Mailing Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022
Business Address C/O ORBIMED ADVISORS LLC 601 LEXINGTON AVE, 54TH FLR. NEW YORK NY 10022 212-739-6451
Edgewise Therapeutics, Inc. (Issuer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address WELLINGTON ALTERNATIVE INVESTMENTS LLC 280 CONGRESS STREET BOSTON MA 02210
Business Address WELLINGTON ALTERNATIVE INVESTMENTS LLC 280 CONGRESS STREET BOSTON MA 02210 (617) 951-5372
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. (Reporting) CIK: 0001787092 (see all company filings)

State of Incorp.: E9
Type: 3 | Act: 34 | File No.: 001-40236 | Film No.: 21774360